Emerging Company Profile
XWPharma: timing therapy to biological rhythm
XWPharma to use $40M series C to advance two lead neurology programs
XWPharma develops CNS therapies with validated targets using novel formulations to synchronize with the body’s natural rhythm.
Wuhan-based XWPharma is developing novel formulations of existing neurology drugs designed to synchronize